Home › Funds › GILEAD SCIENCES, INC. › LKFT

GILEAD SCIENCES, INC. position in LKFT

Lakefront Biotherapeutics

GILEAD SCIENCES, INC. reported holding 16,707,477 shares of LKFT (Lakefront Biotherapeutics) in its Q3 2026 13F filing — a position valued at US$501.3M, representing 34.24% of its reported portfolio and ranking #2 among its reported holdings. GILEAD SCIENCES, INC. has disclosed LKFT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)16.71M sh
Reported value held$501.28M
Portfolio Weight34.24%
First reportedQ4 2024
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GILEAD SCIENCES, INC.'s LKFT position evolved

GILEAD SCIENCES, INC. first disclosed a stake in LKFT in Q4 2024 at 16,707,477 shares (US$461.7M). The position peaked in Q3 2025 at 16,707,477 shares, worth US$578.7M. Across 8 filings, GILEAD SCIENCES, INC. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 16,707,477 shares valued at US$501.3M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 16.71M $461.73M New
Q1 2025 16.71M $419.39M Hold
Q2 2025 16.71M $467.64M Hold
Q3 2025 16.71M $578.75M Hold
Q4 2025 16.71M $550.62M Hold
Q1 2026 16.71M $501.22M Hold
Q2 2026 16.71M $500.16M Hold
Q3 2026 16.71M $501.28M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LKFT and 13F data

LKFT (Lakefront Biotherapeutics) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M), Prosight Management, LP (US$61.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LKFT

All LKFT fund holders →

FAQ

How long has GILEAD SCIENCES, INC. held LKFT?

GILEAD SCIENCES, INC. has disclosed LKFT holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is GILEAD SCIENCES, INC.'s current position in LKFT?

As of Q3 2026, GILEAD SCIENCES, INC. holds 16.71M shares of LKFT (Lakefront Biotherapeutics), valued at $501.28M, representing 34.24% of its reported portfolio and ranking #2.

Has GILEAD SCIENCES, INC. been buying or selling LKFT?

In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in LKFT. The position peaked in Q3 2025 at 16.71M shares.

Which other funds hold LKFT?

Other major institutional holders of LKFT include TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, Prosight Management, LP, among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.